Side-by-side · Research reference

BPC-157vsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed9/53 cited

BPhase 3Reviewed8/39 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

BPC-157

Thymosin α-1

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014 Sikiric 2018

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

No known endogenous receptor; mechanism still under investigation

—

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

BPC-157

Thymosin α-1

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

—

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

2× weekly (Mon/Thu typical)

Lower / starter dose

200 mcg / day

Conservative starter for new users.

0.8 mg per injection

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

6–12 months for chronic indications

Reconstitution

Bacteriostatic water, 1–2 mL

Sterile water for injection per vial label

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

No specific time

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

~2 hours plasma; tissue effect days

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

04Side Effects & Safety

Parameter

BPC-157

Thymosin α-1

Injection site reaction

Mild irritation (anecdotal)

Erythema, mild discomfort

GI symptoms

None reported in PL-14736 Phase 2

Rare nausea

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

No signal — used as adjuvant in oncology

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

Avoid

Long-term safety

Unknown beyond Phase 2 trial duration

—

Drug interactions

None established

—

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

BPC-157

Thymosin α-1

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

2× weekly, e.g. Monday + Thursday.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

Thymosin α-1

— no documented stacks